
浏览全部资源
扫码关注微信
纸质出版:2016
移动端阅览
张瑞凤,毕东敏,游忠岚,田展飞,王宇明,周智宏,张国顺,余亮科,宋敬华,袁强.扶正化瘀胶囊联合替诺福韦治疗乙肝肝纤维化的疗效观察[J].陆军军医大学学报(原第三军医大学学报),2016,38(21):2363-2367.
Zhang Ruifeng,Bi Dongmin,You Zhonglan,Tian Zhanfei,Wang Yuming,Zhou Zhihong,Zhang Guoshun,Yu Liangke,Song Jinghua,Yuan Qiang.Efficiency of Fuzheng Huayu Capsule combined with tenofovir in treatment of hepatitis B liver fibrosis[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(21):2363-2367.
张瑞凤,毕东敏,游忠岚,田展飞,王宇明,周智宏,张国顺,余亮科,宋敬华,袁强.扶正化瘀胶囊联合替诺福韦治疗乙肝肝纤维化的疗效观察[J].陆军军医大学学报(原第三军医大学学报),2016,38(21):2363-2367. DOI:
Zhang Ruifeng,Bi Dongmin,You Zhonglan,Tian Zhanfei,Wang Yuming,Zhou Zhihong,Zhang Guoshun,Yu Liangke,Song Jinghua,Yuan Qiang.Efficiency of Fuzheng Huayu Capsule combined with tenofovir in treatment of hepatitis B liver fibrosis[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(21):2363-2367. DOI:
目的 观察扶正化瘀胶囊联合替诺福韦治疗乙肝肝纤维化的疗效。方法 对116例慢乙肝肝纤维化患者的临床资料进行回顾性分析,根据用药的不同,分为单药组和联合组。单药组(56例)服用替诺福韦 300 mg/次,1次/d,疗程72周;联合组(60例)服用替诺福韦(剂量及其疗程同单药组)加扶正化瘀胶囊1.5 g/次,3次/d,疗程72周;观察比较其治疗前后肝功能指标、乙肝病毒(HBV)DNA定量、HBV血清学标志物、肝纤维化4项、腹部超声及Fibrosean测量指标肝脏硬度值(LSM)肝纤维化无创指标的变化。结果两组患者肝功能均恢复正常;HBV DNA<500 拷贝/mL的比例分别为82.14%(46/56)、86.67%(52/ 60),差异无统计学意义(P0.05);HBeAg血清学转换率为21.43%(12/56)、23.33%(14/60),差异无统计学意义(P0.05);联合组肝纤维化4项指标较单药组显著下降(P0.05);治疗后腹部超声检测指标门静脉直径、门静脉血流速度、脾脏厚度和门脉血流量组间比较差异均有统计学意义(P0.05);LSM值治疗后均降低,且联合组与单药组比较,差异有统计学意义(P0.05)。结论 采用扶正化瘀胶囊与替诺福韦联合治疗乙肝肝纤维化较单纯西药疗效显著,是值得临床推广的新方法。
Objective To determine the curative effect of Fuzheng Huayu Capsule (a prescription of traditional Chinese medicine based on anti-viral herbs) combined with tenofovir in treatment of hepatitis B liver fibrosis. Methods Clinical data of 116 patients with chronic hepatitis B liver fibrosis who admitted in the Southwest Hospital and the Affiliated Hospital of North China University of Science and Technology from July 2014 to January 2016 were collected and retrospectively analyzed. According to their treatment
the patients were divided into the single drug group (n=56
300 mg/d tenofovir
once per day
for 72 weeks) and the combined group (n=60
tenofovir at the same dose and course as the single drug group combined with 1.5 g Fuzheng Huayu Capsule
3 times per day
for 72 weeks). The liver function
HBV DNA copy number
HBV serological indicators
liver fibrosis indicators were measured
and abdomen ultrasonography and Fibroscan testing was carried out before and after the treatment. The above indicators and results were compared between the 2 groups. Results The liver function were returned to normal in the both groups of patients. The proportion of the patients with HBV DNA 500 copy/mL was 82.14% (46/56) in the single drug group and 86.67% (52/60) in the combined group
without significant difference (P0.05). The rate of HBeAg sero-conversion was 21.43% (12/56) in the former and 23.33% (14/60) in the latter group
and no statistical significance was found (P0.05). The 4 indicators of liver fibrosis were significantly lower in the combined group than the single drug group (P0.05). After treatment
abdominal ultrasound examination showed that obvious differences were seen in portal vein diameter and blood flow velocity
spleen length and portal blood flow between the 2 groups (P0.05). The liver stiffness measure (LSM) values were decreased after treatment
and statistical significance was observed between the 2 groups (P0.05). Conclusion Combination of Fuzheng Huayu Capsule and tenofovir is more effective in the treatment of hepatitis B liver fibrosis
and it is worthy of clinical promotion.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621